<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906020</url>
  </required_header>
  <id_info>
    <org_study_id>ACT14820</org_study_id>
    <secondary_id>2016-000657-12</secondary_id>
    <secondary_id>U1111-1180-6918</secondary_id>
    <nct_id>NCT02906020</nct_id>
  </id_info>
  <brief_title>A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation</brief_title>
  <acronym>MOVES-PD</acronym>
  <official_title>Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        -  Part 1: To determine the safety and tolerability of GZ/SAR402671 administered orally for&#xD;
           4 weeks, as compared to placebo in patients with early-stage Parkinson's disease (PD)&#xD;
           carrying a GBA mutation or other pre-specified variants.&#xD;
&#xD;
        -  Part 2: To determine the efficacy of GZ/SAR402671 administered orally daily, as compared&#xD;
           to placebo in patients with early-stage Parkinson's disease carrying a GBA mutation or&#xD;
           other pre-specified variants.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      Part 1:&#xD;
&#xD;
        -  To assess the pharmacokinetic (PK) profile of oral dosing of GZ/SAR402671 in plasma when&#xD;
           administered in early-stage Parkinson's disease patients carrying a GBA mutation.&#xD;
&#xD;
        -  To assess the exposure of GZ/SAR402671 in cerebrospinal fluid (CSF) when administered in&#xD;
           early-stage Parkinson's disease patients carrying a GBA mutation.&#xD;
&#xD;
      Part 2:&#xD;
&#xD;
        -  To demonstrate overall safety and tolerability of GZ/SAR402671 administered orally for&#xD;
           52 weeks in early-stage Parkinson's disease patients carrying a GBA mutation as compared&#xD;
           to placebo.&#xD;
&#xD;
        -  To assess the pharmacodynamic response to daily oral dosing of GZ/SAR402671 in plasma&#xD;
           and CSF as measured by glucosylceramide (GL-1) when administered in early-stage&#xD;
           Parkinson's disease patients carrying a GBA mutation over a 52-week period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: the total duration will be up to approximately 50 weeks (or 68 weeks in Japan). Part&#xD;
      2: the total duration will be up to approximately 222 weeks that will consist of 8.5 weeks of&#xD;
      screening period, 52 weeks of treatment period, 156 weeks of long term follow-up period and 8&#xD;
      weeks of post-treatment period.&#xD;
&#xD;
      At the end of a 52-week main placebo-controlled treatment period, all patients will be&#xD;
      evaluated for possibility to transition to receive active treatment for 156 weeks plus 8 week&#xD;
      post-treatment observation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The topline results of the 52-week double-blind placebo-controlled period were analyzed. The&#xD;
    study did not meet the primary or secondary endpoints. Based on these results, the decision was&#xD;
    made to halt the long-term follow-up period of the study.&#xD;
  </why_stopped>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Actual">May 27, 2021</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of patients with AE</measure>
    <time_frame>During treatment emergent period (from first IMP to 6 weeks after last IMP)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part II and III score, performed during the OFF state</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in Parkinson's Disease Cognitive Rating Scale (total score)</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part I, II, and III score, performed during the OFF state</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in Hoehn and Yahr score</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>GZ/SAR402671</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Increasing dose of GZ/SAR402671 will be administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) will be administered once per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A matching placebo for Parts 1 and 2 will be administered once per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venglustat GZ/SAR402671</intervention_name>
    <description>Pharmaceutical form: capsule Route of administration: oral</description>
    <arm_group_label>GZ/SAR402671</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: capsule Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Male and female adults with a diagnosis of PD and who are heterozygous carriers of a&#xD;
             GBA mutation associated with PD.&#xD;
&#xD;
          -  Patients carrying known sequence variants associated with GBA-PD must have rapid eye&#xD;
             movement (REM) sleep behavior disorder (RBD) confirmed by historically documented&#xD;
             polysomnography or by questionnaire.&#xD;
&#xD;
          -  Age ≥18 years to 80 years inclusive at the time of informed consent signing.&#xD;
&#xD;
          -  Has symptoms of PD ≥2 years.&#xD;
&#xD;
          -  Hoehn and Yahr (H and Y) stage of 2 or lower at baseline.&#xD;
&#xD;
          -  Stable medication regimen of PD drugs for at least 30 days (at least 60 days for&#xD;
             rasagiline) prior to randomization.&#xD;
&#xD;
          -  The patient is willing to abstain from grapefruit containing products for 72 hours&#xD;
             prior to administration of the first dose of GZ/SAR402671 and for duration of the&#xD;
             entire treatment period (Part 1 and Part 2, Periods 2 and 3).&#xD;
&#xD;
          -  Signed written consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Parkinsonism due to drug(s) or toxin(s).&#xD;
&#xD;
          -  Patients carrying the LRRK2 G2019S mutation.&#xD;
&#xD;
          -  Patients with Gaucher disease (GD) as defined by clinical signs and symptoms (ie,&#xD;
             hepatosplenomegaly, cytopenia, skeletal disease) and/or marked deficiency of GCase&#xD;
             activity compatible with GD.&#xD;
&#xD;
          -  Montreal Cognitive Assessment score &lt;20.&#xD;
&#xD;
          -  Patients with prior surgical history of deep brain stimulation (DBS).&#xD;
&#xD;
          -  Patients with baseline brain MRI without contrast showing a structural abnormality&#xD;
             that is a possible cause of their PD signs or symptoms.&#xD;
&#xD;
          -  Hepatic insufficiency with liver function tests (LFT) &gt;2 times upper limit of normal&#xD;
             at Screening Visit.&#xD;
&#xD;
          -  The patient has a documented diagnosis, as per local regulations, of any of the&#xD;
             following infections: hepatitis B, hepatitis C, human immunodeficiency virus 1 or 2.&#xD;
&#xD;
          -  Renal insufficiency as defined by creatine &gt;1.5 times normal at Screening Visit.&#xD;
&#xD;
          -  The patient has received strong or moderate inducers or inhibitors of CYP3A4 within 30&#xD;
             days or 5 half-lives prior to randomization, whichever is longer.&#xD;
&#xD;
          -  The patient has, according to World Health Organization (WHO) Grading, a cortical&#xD;
             cataract &gt; one-quarter the lens circumference (grade cortical catact-2 [COR-2]) or a&#xD;
             posterior subcapsular cataract &gt;2 mm (grade posterior subscapsular cataract [PSC-2]).&#xD;
             Patient with nuclear cataracts will not be excluded.&#xD;
&#xD;
          -  The patient is currently receiving potentially cataractogenic medications, including&#xD;
             chronic regimen (more frequently than every 2 weeks) of any dose or route of&#xD;
             corticosteroids or any medication that can cause cataract or worsen the vision of&#xD;
             patients with cataract (eg, glaucoma medications) according to the Prescribing&#xD;
             Information.&#xD;
&#xD;
          -  If female, pregnancy (defined as positive beta-human chorionic gonadotrophin&#xD;
             [Beta-HCG] blood test) or lactating or breast-feeding.&#xD;
&#xD;
          -  Any medical disorders and/or clinically relevant findings that, in the opinion of the&#xD;
             Investigator, could interfere with study-related procedures. This includes&#xD;
             condition(s) that preclude the safe performance of routine lumbar punctures, such as&#xD;
             prohibitive spinal diseases, bleeding diasthesis, or clinically significant&#xD;
             coagulopathy or thrombocytopenia.&#xD;
&#xD;
          -  Current participation in another investigational interventional study.&#xD;
&#xD;
          -  Any medications specifically used for treating memory dysfunction, such as, but not&#xD;
             limited to cholinesterase inhibitors or memantine, within 30 days or 5 half-lives of&#xD;
             these medications prior to randomization, whichever is longer.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 8400017</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400011</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400004</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400019</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400013</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400015</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400008</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400016</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400005</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400014</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400018</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400010</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400021</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400020</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400009</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400006</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400012</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0400001</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Montreal</city>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240002</name>
      <address>
        <city>Ottawa</city>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240003</name>
      <address>
        <city>Vancouver</city>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760002</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760001</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3000004</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3000002</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3760002</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3760003</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3760001</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3760004</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800004</name>
      <address>
        <city>Milano</city>
        <zip>20126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800006</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800002</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920001</name>
      <address>
        <city>Bunkyo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920003</name>
      <address>
        <city>Kodaira-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920002</name>
      <address>
        <city>Kyoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920005</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920004</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5780001</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200002</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200003</name>
      <address>
        <city>Torres Vedras</city>
        <zip>2560-280</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7020001</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7020002</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7520001</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580001</name>
      <address>
        <city>Taoyuan County</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260001</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260002</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

